Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Dalton Drops ASKA Stake Increase Plan, Slams Firm’s “Self-Preservation”
ASKA Pharmaceutical Holdings said on September 30 that it has received a letter from US investment fund Dalton Investments and its partners stating that they will no longer pursue a plan to raise their stake in the Japanese drug maker.…
To read the full story
Related Article
- ASKA Keeps Defense Policy in Place as Dalton Dispute Persists
October 15, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- Dalton Signals Plan to Lift ASKA Stake to 30%; Board Weighs Countermeasures
August 19, 2025
- ASKA Moves to Counter Dalton Investments’ Rapid Share Purchase
July 2, 2025
BUSINESS
- Lilly’s Omvoh 200 mg SC Wins Japan Nod for UC Maintenance Use
April 17, 2026
- Sobi Japan Shoots for 8 to 9-Fold Growth by 2030 on Five Approvals
April 17, 2026
- Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
April 16, 2026
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…